3D Bioprinted Human Tissue Market is predicted to reach USD 5.34 billion at a CAGR of 8.80% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global 3D Bioprinted Human Tissue Market”.

The 3D Bioprinted Human Tissue Market is estimated to register a CAGR of 8.80% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global 3D Bioprinted Human Tissue Market— 3D Bioprinting Solutions, Allevi, Cellink Global, Cyfuse Biomedical K.K., EnvisionTEC, Inc., Inventia Life Science PTY LTD, Organovo Holdings, Inc., Poietis, Regemat 3D S.L., Vivax Bio, LLC.

3D Bioprinted Human Tissue Market Highlights

The global 3D Bioprinted Human Tissue Market is accounted to register a CAGR of 8.80% during the forecast period and is estimated to reach USD 5.34 billion by 2032.

The 3D Bioprinted Human Tissue market's growth is driven by several factors, such as an aging population dealing with chronic respiratory illnesses and an ongoing scarcity of organ donors. Moreover, the manufacturing of tissue and bones, liver modeling, cancer therapy, and epidermal layer growth are among the key technical advancements in the field of 3D bioprinting that are anticipated to have a substantial impact on the market over the course of the forecast period.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of 3D Bioprinted Human Tissue Market

Segment Analysis

The global 3D Bioprinted Human Tissue Market has been segmented based on Technology and Application.

Based on the Technology, the market is segmented into Magnetic Levitation Bioprinting, Inkjet Bioprinting, Syringe/Extrusion Bioprinting, and Laser-Assisted Bioprinting. The Inkjet Bioprinting segment was attributed to holding the largest market share in 2023 primarily due to its capability to print complex living organs or tissues on culture substrates using biomaterials like bio-inks. The widespread adoption of inkjet-based printing in the medical sector is driving the growth of this segment. This study explores the research trends in inkjet printing as a bio-applicable technology, particularly in the realms of tissue engineering and drug delivery systems.

Based on the Application, the 3D Bioprinted Human Tissue Market has been segmented into Drug Testing and Development, Regenerative Medicine, Clinical Application, Food Testing, and Research. The drug testing and development segment was expected to hold the largest market share in 2023. 3D bioprinted human tissue plays a crucial role in drug testing and clinical trials. Their significance lies in their potential to significantly reduce the reliance on animal trials, offering ethical benefits and cost-effectiveness. Traditionally, drug development involved testing on animals with artificially induced affected tissues. However, the emergence of 3D bioprinted human tissue allows drug developers to address complications associated with human clinical trials more efficiently. By utilizing human-like 3D-printed tissues, potential issues with new drugs can be identified in a shorter timeframe, reducing losses incurred during late-stage failures. An article published by the National Library of Medicine in September 2021 highlights how 3D printing enhances drug screening platforms by accurately depositing biomaterials containing patient-derived cells, thereby reproducing the natural environment of the diseased human body.

Regional Analysis

The global 3D Bioprinted Human Tissue Market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The European 3D Bioprinted Human Tissue Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The 3D Bioprinted Human Tissue Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World 3D Bioprinted Human Tissue Market comprises the Middle East, Africa, and Latin America.

The largest market share for the 3D Bioprinted Human Tissue Market was maintained by the North American regional sector. The growing integration of IT in the healthcare sector is expected to drive growth. According to the World Meter Report 2021, the US alone reported approximately 23,369,732 active cases of COVID-19 until January 13, 2021, with over 50 vaccine candidates in various stages of trials. Increased government spending on research and development for vaccine development is fueling demand for 3D bioprinting technology, which has been recognized for its applications in drug testing and organ transplantation.

Moreover, the Europe market has been persistently growing over the forecast period as the lack of organs continues to be a major worldwide issue, particularly in Europe. By providing a substitute for traditional organ transplantation, 3D bioprinting offers a potential direction. With 112.4 transplants per million people, Spain had the greatest organ transplant rate in 2022. This was a rise of almost 13 over 2021, and it was the highest rate increase among European countries. With 81.8 transplants per million in 2022, Belgium had the second-highest rate behind Spain. While completely functional 3D bioprinted organs for transplantation are still in the early phases of development, tissue engineering advancements are setting the way for their future manufacturing.

The adoption of 3D printing in China is rapidly accelerating in comparison to other developed economies like North America and Europe despite not being among the earliest adopters of the technology. A key driver behind this growth is the strong support from the Chinese government for innovation, development, and integration of technology across various industries in the country. Medprin Regenerative Medical Technologies, a Chinese medical device company specializing in 3D printing technology, recently secured 1.1 billion yuan ($170 million) in a series B funding round. The company intends to utilize these funds to enhance its research and development capabilities and to expand the production of its products. It helps in the quickest growth of Asia-Pacific market, empowering research institutes to advance their developments. The Japanese government projects that the regenerative medicine industry will achieve a revenue of JPY 1 trillion by 2030. The New Energy and Industrial Technology Development Organization (NEDO) anticipates that emerging and innovative technologies, such as 3D bioprinting, will likely dominate the market shortly.

Furthermore, the rest of the world's 3D Bioprinted Human Tissue Market is divided into the Middle East, Africa, and Latin America. The increasing prevalence of chronic diseases and aging populations is fueling the need for advanced medical interventions. According to the WHO, between half and 88% of deaths in seven African countries are attributed to chronic diseases. 3D bioprinting presents promising avenues for tissue engineering and regenerative medicine, particularly beneficial for individuals grappling with age-related degenerative conditions or traumatic injuries.

Key Findings of the Study

• The global 3D Bioprinted Human Tissue Market is expected to reach USD 5.34 billion by 2032, at a CAGR of 8.80% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market because of the increasing incidence of COVID-19 and increased government investment in R&D.


• Based on Technology, the Inkjet Bioprinting segment was attributed to holding the largest market in 2023.


• 3D Bioprinting Solutions, Allevi, Cellink Global, Cyfuse Biomedical K.K., EnvisionTEC, Inc., Inventia Life Science PTY LTD, Organovo Holdings, Inc., Poietis, Regemat 3D S.L., and Vivax Bio, LLC are the key market players.